● pepmg Research Desk · Peer-reviewed evidence review
What the research says about NAD+
A neutral summary of the peer-reviewed literature on NAD+, a coenzyme central to metabolism whose age-related decline is studied mostly in preclinical models. Human trials largely test oral precursors, not injected NAD+, and report limited efficacy. Research use only.
Limited evidence — Early or small human data, or strong preclinical work. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to energy metabolism and a cosubstrate for enzymes such as the sirtuins; its tissue levels decline with age in the models reviewed [1][3].
- Most of the evidence that raising NAD+ is beneficial comes from preclinical (cell and animal) studies [3][5].
- Human clinical trials have largely tested oral precursors (NMN and NR) rather than injected NAD+ itself, and reviews report limited efficacy so far [4][5].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or dosing guidance. Research use only.
What NAD+ is
NAD+ is described in the literature as a coenzyme found in all living cells that carries electrons in reduction-oxidation reactions and serves as a cosubstrate for non-redox enzymes including the sirtuins, CD38, and poly(ADP-ribose) polymerases [1][2]. Through these roles it influences energy metabolism, DNA repair, chromatin remodeling, cellular senescence, and immune function [1]. NAD+ sold by third-party research-chemical vendors, including injectable preparations, is offered for laboratory and research use only.
Much of the therapeutic interest centers not on NAD+ delivered directly, but on strategies to raise cellular NAD+, including its precursor molecules [3][5].
What the research has measured
Limited evidenceReviews report that cellular and tissue NAD+ levels decline during aging across model organisms, and that this decline has been linked to numerous age-associated conditions [1][6]. In preclinical settings, various strategies to restore NAD+ levels have shown benefits on metabolism, mitochondrial and stem-cell function, and healthspan or lifespan measures in animals [3][5]. Two precursor molecules, nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), have been the most extensively studied NAD+ intermediates and have shown preventive and therapeutic effects in animal models [5].
The translation to humans is where the evidence thins. A 2025 review evaluating the clinical evidence reported that an age-related decline in human NAD+ has been consistently observed in only a limited number of studies, that human clinical trials of NAD+ precursor supplementation have shown limited efficacy, and that the body of data on NAD+ dynamics in human tissues remains sparse, cautioning that rodent results do not extrapolate straightforwardly [4]. Much of the human work tests oral precursors, not injected NAD+ itself [4][5].
What the trials report on safety and adverse events
Limited evidenceBecause most human evidence involves oral NAD+ precursors rather than injected NAD+, safety data specific to injectable NAD+ are scarce. Reviews of the field frame safety as an open question, noting that whether restoring NAD+ during human aging is effective and safe remains to be established, and that more clinical studies are needed [1][4].
There are no large controlled trials establishing the safety or efficacy of injected NAD+ for anti-aging or metabolic uses. This is not medical advice; the human safety of injectable NAD+ is not established. Consult a qualified professional and read the studies directly.
How strong is the evidence
The basic biology of NAD+ is well established, but the evidence that raising NAD+ improves human health is characterized as limited: it rests largely on preclinical studies, while human trials, mostly of oral precursors, have shown limited efficacy and remain sparse [3][4][5]. "Limited" describes the state of the translational research, not a judgment of whether NAD+ supplementation works or is safe.
Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 6
- NAD+ metabolism and its roles in cellular processes during ageing.
- NAD+ in aging, metabolism, and neurodegeneration.
- Therapeutic potential of NAD-boosting molecules: the in vivo evidence.
- NAD+ precursor supplementation in human ageing: clinical evidence and challenges.
- NAD+ intermediates: the biology and therapeutic potential of NMN and NR.
- NAD+ homeostasis in health and disease.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.